CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
F-18 Fluoro-deoxi-glucose +4 moredrug
Likely dose
Sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00537056
NCT00537056N/ACompleted
CompareCT.gov

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Stanford University·interventional·Posted Sep 28, 2007·Updated Jun 14, 2017

In Brief

A clinical study evaluating FDG PET CT, DCE MRI, and 3 other interventions for Kidney Neoplasms and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2007
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.8 years ago

Interventions

FDG PET CTprocedure

nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body

DCE MRIprocedure

DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).

F-18 Fluoro-deoxi-glucosedrug

15 mCi iv

Gadolinium-DTPAdrug

0.1 mmol/kg iv

Sunitinibdrug

50 mg/day po